Development and treatment of tertiary hyperparathyroidism in patients with pseudohypoparathyroidism type 1B

Nicola M. Neary, Diala El-Maouche, Rachel Hopkins, Steven K. Libutti, Arnold M. Moses, Lee S. Weinstein

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Context: Pseudohypoparathyroidism type 1B (PHP1B) patients have PTH resistance at the renal proximal tubule and develop hypocalcemia and secondary hyperparathyroidism. Hyperparathyroid bone disease also develops in some patients. PHP1B patients are at theoretical risk of developing tertiary hyperparathyroidism. Setting: Patients were studied in a clinical research center. Patients: Five female PHP1B patients presented with hypercalcemia and elevated PTH. Intervention: Patients either underwent parathyroidectomy (n = 4) or received cinacalcet (n = 1). Main Outcome Measures: Serum calcium and PTH were serially measured before and after intervention. Results: Five PHP1B patients developed concomitantly elevated serum calcium and PTH levels (range, 235-864 ng/liter) requiring termination of calcium and vitamin D therapy (time after diagnosis, 21-42 yr; median, 34 yr), consistent with tertiary hyperparathyroidism. Four patients underwent parathyroidectomy with removal of one (n = 2) or two (n = 2) enlarged parathyroid glands. Calcium and vitamin D therapy was reinstituted postoperatively, and at 93-month median follow-up, PTH levels ranged between 56 and 182 (normal, <87) ng/liter. One patient was treated with cinacalcet, resulting in resolution of hypercalcemia. Conclusions: PHP1B patients are at risk of developing tertiary hyperparathyroidism and/or hyperparathyroid bone disease and should therefore be treated with sufficient doses of calcium and vitamin D to achieve serum calcium and PTH levels within or as close to the normal range as possible. Surgery is the treatment of choice in this setting. Cinacalcet may be a useful alternative in those who do not undergo surgery.

Original languageEnglish (US)
Pages (from-to)3025-3030
Number of pages6
JournalJournal of Clinical Endocrinology and Metabolism
Volume97
Issue number9
DOIs
StatePublished - Sep 2012
Externally publishedYes

Fingerprint

Hyperparathyroidism
Calcium
Vitamin D
Surgery
Bone
Therapeutics
Parathyroidectomy
Bone Diseases
Hypercalcemia
Pseudohypoparathyroidism Type 1B
Serum
Proximal Kidney Tubule
Secondary Hyperparathyroidism
Parathyroid Glands
Hypocalcemia
Reference Values
Cinacalcet Hydrochloride
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Endocrinology
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism

Cite this

Development and treatment of tertiary hyperparathyroidism in patients with pseudohypoparathyroidism type 1B. / Neary, Nicola M.; El-Maouche, Diala; Hopkins, Rachel; Libutti, Steven K.; Moses, Arnold M.; Weinstein, Lee S.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 97, No. 9, 09.2012, p. 3025-3030.

Research output: Contribution to journalArticle

Neary, Nicola M. ; El-Maouche, Diala ; Hopkins, Rachel ; Libutti, Steven K. ; Moses, Arnold M. ; Weinstein, Lee S. / Development and treatment of tertiary hyperparathyroidism in patients with pseudohypoparathyroidism type 1B. In: Journal of Clinical Endocrinology and Metabolism. 2012 ; Vol. 97, No. 9. pp. 3025-3030.
@article{1d8c07e5ceb748eb9962d00ede44d3ca,
title = "Development and treatment of tertiary hyperparathyroidism in patients with pseudohypoparathyroidism type 1B",
abstract = "Context: Pseudohypoparathyroidism type 1B (PHP1B) patients have PTH resistance at the renal proximal tubule and develop hypocalcemia and secondary hyperparathyroidism. Hyperparathyroid bone disease also develops in some patients. PHP1B patients are at theoretical risk of developing tertiary hyperparathyroidism. Setting: Patients were studied in a clinical research center. Patients: Five female PHP1B patients presented with hypercalcemia and elevated PTH. Intervention: Patients either underwent parathyroidectomy (n = 4) or received cinacalcet (n = 1). Main Outcome Measures: Serum calcium and PTH were serially measured before and after intervention. Results: Five PHP1B patients developed concomitantly elevated serum calcium and PTH levels (range, 235-864 ng/liter) requiring termination of calcium and vitamin D therapy (time after diagnosis, 21-42 yr; median, 34 yr), consistent with tertiary hyperparathyroidism. Four patients underwent parathyroidectomy with removal of one (n = 2) or two (n = 2) enlarged parathyroid glands. Calcium and vitamin D therapy was reinstituted postoperatively, and at 93-month median follow-up, PTH levels ranged between 56 and 182 (normal, <87) ng/liter. One patient was treated with cinacalcet, resulting in resolution of hypercalcemia. Conclusions: PHP1B patients are at risk of developing tertiary hyperparathyroidism and/or hyperparathyroid bone disease and should therefore be treated with sufficient doses of calcium and vitamin D to achieve serum calcium and PTH levels within or as close to the normal range as possible. Surgery is the treatment of choice in this setting. Cinacalcet may be a useful alternative in those who do not undergo surgery.",
author = "Neary, {Nicola M.} and Diala El-Maouche and Rachel Hopkins and Libutti, {Steven K.} and Moses, {Arnold M.} and Weinstein, {Lee S.}",
year = "2012",
month = "9",
doi = "10.1210/jc.2012-1655",
language = "English (US)",
volume = "97",
pages = "3025--3030",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "9",

}

TY - JOUR

T1 - Development and treatment of tertiary hyperparathyroidism in patients with pseudohypoparathyroidism type 1B

AU - Neary, Nicola M.

AU - El-Maouche, Diala

AU - Hopkins, Rachel

AU - Libutti, Steven K.

AU - Moses, Arnold M.

AU - Weinstein, Lee S.

PY - 2012/9

Y1 - 2012/9

N2 - Context: Pseudohypoparathyroidism type 1B (PHP1B) patients have PTH resistance at the renal proximal tubule and develop hypocalcemia and secondary hyperparathyroidism. Hyperparathyroid bone disease also develops in some patients. PHP1B patients are at theoretical risk of developing tertiary hyperparathyroidism. Setting: Patients were studied in a clinical research center. Patients: Five female PHP1B patients presented with hypercalcemia and elevated PTH. Intervention: Patients either underwent parathyroidectomy (n = 4) or received cinacalcet (n = 1). Main Outcome Measures: Serum calcium and PTH were serially measured before and after intervention. Results: Five PHP1B patients developed concomitantly elevated serum calcium and PTH levels (range, 235-864 ng/liter) requiring termination of calcium and vitamin D therapy (time after diagnosis, 21-42 yr; median, 34 yr), consistent with tertiary hyperparathyroidism. Four patients underwent parathyroidectomy with removal of one (n = 2) or two (n = 2) enlarged parathyroid glands. Calcium and vitamin D therapy was reinstituted postoperatively, and at 93-month median follow-up, PTH levels ranged between 56 and 182 (normal, <87) ng/liter. One patient was treated with cinacalcet, resulting in resolution of hypercalcemia. Conclusions: PHP1B patients are at risk of developing tertiary hyperparathyroidism and/or hyperparathyroid bone disease and should therefore be treated with sufficient doses of calcium and vitamin D to achieve serum calcium and PTH levels within or as close to the normal range as possible. Surgery is the treatment of choice in this setting. Cinacalcet may be a useful alternative in those who do not undergo surgery.

AB - Context: Pseudohypoparathyroidism type 1B (PHP1B) patients have PTH resistance at the renal proximal tubule and develop hypocalcemia and secondary hyperparathyroidism. Hyperparathyroid bone disease also develops in some patients. PHP1B patients are at theoretical risk of developing tertiary hyperparathyroidism. Setting: Patients were studied in a clinical research center. Patients: Five female PHP1B patients presented with hypercalcemia and elevated PTH. Intervention: Patients either underwent parathyroidectomy (n = 4) or received cinacalcet (n = 1). Main Outcome Measures: Serum calcium and PTH were serially measured before and after intervention. Results: Five PHP1B patients developed concomitantly elevated serum calcium and PTH levels (range, 235-864 ng/liter) requiring termination of calcium and vitamin D therapy (time after diagnosis, 21-42 yr; median, 34 yr), consistent with tertiary hyperparathyroidism. Four patients underwent parathyroidectomy with removal of one (n = 2) or two (n = 2) enlarged parathyroid glands. Calcium and vitamin D therapy was reinstituted postoperatively, and at 93-month median follow-up, PTH levels ranged between 56 and 182 (normal, <87) ng/liter. One patient was treated with cinacalcet, resulting in resolution of hypercalcemia. Conclusions: PHP1B patients are at risk of developing tertiary hyperparathyroidism and/or hyperparathyroid bone disease and should therefore be treated with sufficient doses of calcium and vitamin D to achieve serum calcium and PTH levels within or as close to the normal range as possible. Surgery is the treatment of choice in this setting. Cinacalcet may be a useful alternative in those who do not undergo surgery.

UR - http://www.scopus.com/inward/record.url?scp=84866152271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866152271&partnerID=8YFLogxK

U2 - 10.1210/jc.2012-1655

DO - 10.1210/jc.2012-1655

M3 - Article

C2 - 22736772

AN - SCOPUS:84866152271

VL - 97

SP - 3025

EP - 3030

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 9

ER -